ESTRO 2024 - Abstract Book

S2575

Clinical - Urology

ESTRO 2024

Conclusion:

Among patients treated with SABR for high-risk prostate cancer, DVCs calculated from averaged pre-fraction CBCT datasets appeared to have stronger correlations with acute and late patient-reported bowel QOL, compared to the same DVCs calculated from the planning CT, particularly for higher dose regions. These data suggest that CBCT datasets may be a better predictor of patient-reported bowel QOL for this patient cohort. Data support the implementation of personalised radiotherapy in prostate cancer particularly given the reduced number of fractions with SABR compared to conventional radiotherapy. It is important to note, however, that correlations were weak. Further research, therefore, is indicated using a larger sample size to validate these findings.

Keywords: Stereotactic, inter-fraction motion, outcomes

References:

1. Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health. 2007;10 Suppl 2:S94-s105.

2. Gómez-Millán J, Lara MF, Correa Generoso R, Perez-Rozos A, Lupiáñez-Pérez Y, Medina Carmona JA. Advances in the treatment of prostate cancer with radiotherapy. Crit Rev Oncol Hematol. 2015;95(2):144-53.